Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - vincristine is effective in hodgkins disease and other lymphomas. in hodgkins disease it is effective for the advanced stages (iii and iv) when used in the mopp regime (mechlorethamine, oncovin, prednisone, procarbazine). in non-hodgkins lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin and prednisone. vincristine is also effective in lymphocytic leukemia. beneficial responses have been reported in patients with a variety of other neoplasms, particularly wilms tumour, neuroblastoma, brain tumours, rhabdomyosarcoma and carcinomas of the breast, bladder, and the female and male reproductive systems.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - vincristine sulphate is used either alone or in combination with other oncolytic agents for the treatment of the following conditions: 1. leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia. 2. malignant lymphoma, including hodgkin's lymphoma and non-hodgkin's lymphoma. 3. multiple myeloma 4. solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcoma. 5. paediatric solid tumours, including ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, wilms' tumour, retinoblastoma and medulloblastoma. 6. idiopathic thrombocytopenic purpura (itp). patients with true itp refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine, but the medicinal product is not recommended as primary treatment of this disorder. recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remission in some patients. if patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - vincristine sulfate is indicated alone or in combination with other antitumor therapies for the treatment of: leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic mylogenous leukaemia, malignant lymphomas, including hodgkin?s disease and non-hodgkin?s lymphomas lung cancer (small cell bronchogenic carcinoma) wilms? tumor neuroblastoma ewing?s sarcomas true idiopathic thrombocytopenic purpura rhabdomyosarcoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections - vincristine is effective in hodgkins disease and other lymphomas. in hodgkins disease it is effective for the advanced stages (iii and iv) when used in the mopp regime (mechlorethamine, oncovin, prednisone, procarbazine). in non-hodgkins lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin and prednisone. vincristine is also effective in lymphocytic leukemia. beneficial responses have been reported in patients with a variety of other neoplasms, particularly wilms tumour, neuroblastoma, brain tumours, rhabdomyosarcoma and carcinomas of the breast, bladder, and the female and male reproductive systems.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections; nitrogen - vincristine sulfate is indicated alone or in combination with other antitumor therapies for the treatment of: -leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic mylogenous leukaemia -malignant lymphomas, including hodgkin?s disease and non-hodgkin?s lymphomas -lung cancer (small cell bronchogenic carcinoma) -wilms? tumor -neuroblastoma -ewing?s sarcomas -true idiopathic thrombocytopenic purpura -rhabdomyosarcoma

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vincristine sulfate 1 mg/ml;  ;   - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml     excipient: mannitol sodium hydroxide sulfuric acid water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections - chile vincristine sulfate is indicated alone or in combination with other antitumor therapies for the treatment of: ? leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic mylogenous leukaemia. ? malignant lymphomas, including hodgkin?s disease and non-hodgkin?s lymphomas ? lung cancer (small cell bronchogenic carcinoma) ? wilms? tumor ? neuroblastoma ? ewing?s sarcomas ? true idiopathic thrombocytopenic purpura ? rhabdomyosarcoma ? osteogenic sarcoma ? mycosis fungoides ? uterine cervix cancer ? malignant melanoma ? breast carcinoma croatia vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment but is not recommended as primary treatment for this disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - in combination with other chemotherapeutic agents, vincristine is indicated for the treatment of acute leukaemia and malignant lymphomas, including hodgkin?s disease, lymphosarcoma and reticulosarcoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - in combination with other chemotherapeutic agents, vincristine is indicated for the treatment of acute leukaemia and malignant lymphomas, including hodgkin?s disease, lymphosarcoma and reticulosarcoma.